Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.

Authors

Joseph R Podojil
Alexander P Glaser
Dylan Baker, The Jackson LaboratoryFollow
Elise T Courtois, The Jackson LaboratoryFollow
Damiano Fantini
Yanni Yu
Valerie Eaton
Santhosh Sivajothi, The Jackson LaboratoryFollow
Mingyi Chiang
Arighno Das
Kimberly A McLaughlin
Paul Robson, The Jackson LaboratoryFollow
Stephen D Miller
Joshua J Meeks

Document Type

Article

Publication Date

4-16-2020

Keywords

JGM

JAX Source

Oncoimmunology 2020 Apr 16; 9(1):1744897

Volume

9

Issue

1

First Page

1744897

Last Page

1744897

ISSN

2162-4011

PMID

32363111

DOI

https://doi.org/10.1080/2162402x.2020.1744897

Abstract

Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1-17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory signatures during murine cancer development using the BBN carcinogen and identified an increase in the expression of the T cell inhibitory protein B7-H4 (VTCN1, B7S1, B7X). B7-H4 expression temporally correlated with decreased lymphocyte infiltration. While the increase in B7-H4 expression within the bladder by CD11b

Comments

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License.

Recommended Citation

Podojil J, Glaser A, Baker D, Courtois E, Fantini D, Yu Y, Eaton V, Sivajothi S, Chiang M, Das A, McLaughlin K, Robson P, Miller S, Meeks J. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma. Oncoimmunology 2020 Apr 16; 9(1):1744897